You are here
September 23, 2019
Planning a Virtual Down Syndrome Cohort Across the Lifespan Workshop
DAY 1: Monday, September 23, 2019
Session 1: Welcome and Introductions
8:30鈥8:45 a.m. Welcome Remarks from INCLUDE Leadership
Diana Bianchi, M.D., Director, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
8:45鈥9:05 a.m. Perspectives from a Self-Advocate and Family Member
David Egan, Self-Advocate
Marc Egan, M.S., Brother
9:05鈥9:35 a.m. Setting the Stage: A Vision for an Integrated Down Syndrome Cohort
Melissa Parisi, M.D., Ph.D., NICHD
Session 2A: Existing Down Syndrome Cohorts: Round Robin
Session Chair and Moderator: Charlene Schramm, Ph.D., National Heart, Lung, and Blood Institute (NHLBI)
9:35鈥10:15 a.m. Neurodevelopment and Cardiac Defects in Down Syndrome: The DS 360 Project (DS360)
Tracie Rosser, Ph.D., Emory University
Down Syndrome Cohorts Focusing on Communication and Hearing
Jennifer Kent-Walsh, Ph.D., University of New Mexico and University of Central Florida
Congenital Heart Disease in Down Syndrome and High-Throughput Considerations
Amy Roberts, M.D., Boston Children鈥檚 Hospital
Sleep in Down Syndrome: A Window into Memory Consolidation
Jamie Edgin, Ph.D., University of Arizona
Cardiorespiratory Assessment in Children with Down Syndrome
Ignacio Tapia, M.D., Children鈥檚 Hospital of Philadelphia
Myeloid Malignancies in Down Syndrome
Soheil Meshinchi, M.D, Ph.D., Fred Hutchinson Cancer Research Center
10:15鈥10:45 a.m. BREAK
Session 2B: Existing Down Syndrome Cohorts: Round Robin
Session Chair and Moderator: Robert Riddle, Ph.D., National Institute of Neurological Disorders and Stroke (NINDS)
10:45鈥11:45 a.m. IDDRC Populations and Down Syndrome Cohorts: Standardized Phenotyping Using Large-Scale Database Approaches
Laurie Cutting, Ph.D., Vanderbilt University Medical Center
Cognitive Assessments in Children with Down Syndrome
Anna Esbensen, Ph.D., University of Cincinnati
ABC-DS: Adult Cohorts and Biomarkers for Dementia
Benjamin Handen, Ph.D., University of Pittsburgh
The LonDownS Consortium: Aging in Down Syndrome
Andre Strydom, MRCPsych, Ph.D., King鈥檚 College London
Horizon 21: A European Consortium to Study Alzheimer鈥檚 Disease (AD) in Down Syndrome
Juan Fortea, M.D., Ph.D., Fundaci贸 Catalana S铆ndrome de Down
The Human Trisomy Project (HTP)
Joaquin Espinosa, Ph.D., University of Colorado
LuMind Cohort Studies
James Hendrix, Ph.D., LuMind IDSC Foundation
Recruiting Diverse Populations
Sid O鈥橞ryant, Ph.D., University of North Texas
Session 3: Introduction to the Day 1 Breakout Sessions: Clinical Aspects of Down Syndrome and the 鈥極mics and Biospecimens Needs of the Virtual Cohort
11:45 a.m.鈥 12:00 p.m.
Introduction to the Work Groups and Breakout Sessions
Gail Pearson, M.D., Sc.D., NHLBI
12:00鈥1:00 p.m. LUNCH
Session 4: Day 1 Breakout Sessions
1:00鈥3:30 p.m. Working Groups for Day 1 Breakout Sessions:
A. Co-Occurring Conditions Across the Lifespan (CoC), Room O120
Session Leaders: Marilyn Bull, M.D., Riley Hospital for Children; and Matthew Janicki, Ph.D., National Task Group on Intellectual Disabilities and Dementia Practices
Facilitator: Anna Mazzucco, Ph.D., NIH Office of the Director (OD)
Notetaker: Christina Park, Ph.D., M.H.S., NIH OD/Environmental influences on Child Health Outcomes (ECHO) Program
- What types of clinical and phenotypic data are most valuable to collect for longitudinal and cross-sectional purposes?
- What data elements would comprise a minimum common dataset across all ages and co-occurring conditions?
- How do you add a Down syndrome (DS) component to an existing study?
- How can existing clinical populations (e.g., DS clinics) be leveraged to help build the INCLUDE cohort study?
- What types of subject- and family-entered data are most valuable for cohort studies?
B. 鈥極mics Collections for Down Syndrome Populations (Omic), Room O121
Session Leaders: Amy Brower, Ph.D., American College of Medical Genetics and Genomics; and Philip Lupo, Ph.D., Baylor College of Medicine
Facilitator: Michael Kurilla, M.D., Ph.D., National Center for Advancing Translational Sciences (NCATS)
Notetaker: Huiqing Li, Ph.D., NHLBI
- What existing genomic or other 鈥榦mics datasets can be informative for a larger-scale effort?
- Which 鈥榦mics should we prioritize for collection and long-term analysis?
- Can we anticipate future 鈥榦mics needs, and what would constitute a minimal 鈥榦mics dataset?
- How can we ensure linkages between 鈥榦mics datasets and clinical data?
- What tools are needed to interpret and harmonize these large 鈥榦mics datasets?
C. Biospecimens, Storage, and Distribution (BioS), Room O122
Session Leaders: Tatiana Foroud, Ph.D., Indiana University; and Bernard Khor, M.D., Ph.D., Benaroya Research Institute, Virginia Mason Medical Center
Facilitator: Erika Tarver, M.S.M, National Institute on Aging (NIA)
Notetaker: Christine Guilfoy, Palladian Partners
- How can we encourage individuals with Down syndrome to participate in tissue (including brain tissue) donation efforts?
- What tissues should be prioritized for collection, and how should they be collected?
- Where and how should biospecimens be stored, and can existing biobanks be linked under a common portal to promote access?
- How can we ensure linkages between biospecimens and cohort data?
- What policies and procedures exist to facilitate sharing and access by investigators?
D. Outreach Activities and Participant Engagement (ENG), Room O126
Session Leaders: Ann Cohen, Ph.D., University of Pittsburgh; and Deborah Fidler, Ph.D., Colorado State University
Facilitator: Rebekah Rasooly, Ph.D., National Institute of Nursing Research (NINR)
Notetaker: Sujata Bardhan, Ph.D., NICHD
- What are the best strategies to outreach to the community, including clinicians, researchers, and advocacy groups?
- How can minority populations be encouraged to participate?
- Are there any lessons from existing cohorts, such as All of Us or other minority recruitment efforts, to inform this activity?
- How can registries such as DS-Connect庐 facilitate recruitment for cohort studies and facilitate linkages across datasets?
- What feedback (e.g., results reporting, surveys, newsletters) do families find worthwhile to maintain engagement?
3:30鈥4:00 p.m. BREAK (flexible)
4:00鈥5:30 p.m. Report Back from Each Working Group and Discussion
5:30鈥5:45 p.m. Close of Day 1
DAY 2: September 24, 2019
8:30鈥8:45 a.m. Welcome Remarks from INCLUDE Leadership
Gary Gibbons, M.D., Director, NHLBI
8:45鈥8:55 a.m. Group Picture
8:55鈥9:10 a.m. Overview of Day 1 and Introduction to Day 2
Laurie Ryan, Ph.D., NIA
Session 5: Framing Talks to Prepare for Day 2 Breakout Sessions: Data Integration and Harmonization Among Down Syndrome Cohorts
Session Chair and Moderator: Valerie Cotton, NICHD
9:10鈥9:30 a.m. IT and Data Infrastructure Needs for Interoperability
Allison Heath, M.S., Ph.D., Children鈥檚 Hospital of Philadelphia
9:30鈥9:50 a.m. Challenges for Broad Data Sharing
Jaime Guidry Auvil, Ph.D., National Cancer Institute (NCI) Office of Data Sharing
9:50鈥10:10 a.m. Data Harmonization and Common Data Elements
Nicole Vasilevsky, Ph.D., Oregon Health & Science University
10:10鈥10:30 a.m. Clinical Trial Readiness: Ensuring That Cohort Studies Can Pave the Way for Clinical Trials
Michael Rafii, M.D., Ph.D., Keck School of Medicine of the University of Southern California (USC)
10:30鈥10:40 a.m. Open Discussion
10:40鈥11:10 a.m. BREAK
Session 6: Introduction to the Day 2 Breakout Sessions: Data Integration and Harmonization Among Down Syndrome Cohorts
Session Chair and Moderator: Lawrence Brody, Ph.D., National Human Genome Research Institute (NHGRI)
11:10鈥11:20 a.m. Introduction to the Work Groups and Breakout Sessions
Session 7: Day 2 Breakout Sessions
11:20 a.m.鈥12:30 p.m.
Working Groups for Day 2 Breakout Sessions, Part 1
12:30鈥1:15 p.m. LUNCH (flexible depending on Working Group needs)
1:15鈥2:15 p.m. Working Groups for Day 2 Breakout Sessions, Part 2
Working Groups for Day 2 Breakout Sessions:
E. IT and Data Science Infrastructure Needs for Data Harmonization (IT), Room O120
Session Leaders: Eileen King, Ph.D., Cincinnati Children鈥檚 Hospital; and Russ Waitman, Ph.D., University of Kansas
Facilitator: Erica Rosemond, Ph.D., NCATS
Notetaker: Tara Dutka, Ph.D., National Institute of Mental Health (NIMH)
- What types of data infrastructure can facilitate data sharing or federated data sharing models in accordance with FAIR (Findable, Accessible, Interoperable, Reusable) principles?
- How can we ensure that data systems are interoperable when they are being built? What are some examples that illustrate how to do this?
- What are the common data elements (CDEs) that need to be collected in order to allow harmonization of data across cohorts and comorbidities?
- How can registries such as DS-Connect庐 or National Database for Autism Research (NDAR) facilitate linkages across disparate datasets?
- Are global unique identifiers (GUIDs) truly unique, and how can we ensure data linkages by using different GUID generators?
F. Data Sharing and International Issues (DataS), Room O121
Session Leaders: James Coulombe, Ph.D., NICHD; and Adam Resnick, Ph.D., Children鈥檚 Hospital of Philadelphia
Facilitator: Kelly King, Au.D., Ph.D., National Institute on Deafness and Other Communication Disorders (NIDCD)
Notetaker: Marie Mancini, Ph.D., National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- How can we build a culture of broad data sharing among researchers, advocacy groups, and individuals/families with DS?
- Are there initial steps that can facilitate data sharing in the long run?
- What issues exist that facilitate or deter from gathering broad consent for data sharing, both domestically and internationally?
- Are there special considerations for international cohorts, and how can we address them?
- How can we equitably ensure access to data by other investigators for secondary uses?
G. Registries and Cohort Needs (REG), Room O122
Session Leaders: Scott Kim, M.D., Ph.D., Department of Bioethics, NIH; and Elizabeth Head, Ph.D., University of California, Irvine
Facilitator: Aruna Natarajan, M.D., Ph.D., NHLBI
Notetaker: Rachel Goldman, M.A., NICHD
- What are the special considerations for consenting individuals with reduced decisional capacity?
- How can we 鈥渃onsent across the life span鈥 to ensure that cohorts are re-consented into adulthood and beyond, even if they become impaired?
- How can we ensure that there are systems in place for return of results to participants?
- How can we link biospecimens to registries and promote access?
- How can we promote patient- or subject-entered data for an engaged participant pool?
H. Clinical Trial Readiness (CTR), Room O126
Session Leaders: Ruth Litovsky, Ph.D., University of Wisconsin鈥揗adison; and Mara Becker, M.D., Duke University
Facilitator: Marishka Brown, Ph.D., NHLBI
Notetaker: Lisa Kaeser, J.D., NICHD
- What are the best strategies to outreach to the community, including clinicians, researchers, and advocacy groups?
- What approaches can facilitate recruitment and retention of families/subjects to build the DS cohort and understand natural history, including underrepresented groups?
- How can we build the pipeline of investigators who have DS clinical trial experience?
- How can we ensure that cohorts are prepared for future clinical trials?
- Are there special considerations for clinical trials in those with DS across the life span?
2:15鈥3:30 p.m. Report Back from Each Working Group and Discussion
3:30鈥4:00 p.m. Next Steps, Future Activities, and Closing Remarks
Moderators: Melissa Parisi, M.D., Ph.D., NICHD; and Gail Pearson, M.D., Sc.D., NHLBI
Final Questions: What is missing from our 鈥淏lueprint鈥 for creating a DS cohort across the life span? Are there any other stakeholders that should be involved in this activity? What are the next steps?
4:00 p.m. Close of Day 2
This page last reviewed on February 7, 2020